Vascular Adviser Media Library

Coronary Artery Disease (CAD)

What evidence drove the change in the ESC guidelines in CCS?

Jan Steffel on the new CCS Guidelines

PP-XAR-ALL-1436-1

What evidence drove the change in the ESC guidelines in CCS? 03:37

What is new in the ESC guidelines?

Martin Cowie on the new CCS Guidelines

PP-XAR-ALL-1435-1

What is new in the ESC guidelines? 01:38 min

High-risk Subgroups in COMPASS, CAD Patients with Heart Failure

Kelley Branch on Treatment Strategies

PP-XAR-ALL-0820-1

High-risk Subgroups in COMPASS, CAD Patients with Heart Failure 03:16 min

High-risk Subgroups in COMPASS, Patients with risk of reinfarction

Treatment Strategy for Patients with Prior MI

High-risk Subgroups in COMPASS, Patients with risk of reinfarction 04:02 min

Evolving Management Strategies in CAD

Management strategies and unmet needs in coronary artery disease

Evolving Management Strategies in CAD 04:39 min

What did the CLARIFY and REACH registries tell us about the management of patients with coronary art

A summary and discussion of the CLARIFY and REACH registries

What did the CLARIFY and REACH registries tell us about the management of patients with coronary art 04:19 min

Peripheral Artery Diseases (PAD)

Vascular Protection in Patients with PAD: A Challenge

Better therapeutic options are required in patients with PAD for the prevention of long-term adverse vascular events
Approval Code: PP-XAR-ALL-0212-1

Vascular Protection in Patients with PAD: A Challenge 03:59

Evolving Management Strategies in PAD

Management strategies and unmet needs in peripheral artery disease

Evolving Management Strategies in PAD 07:23 min

ESVS Lunch Symposium

Rivaroxaban Vascular Dose: A Breakthrough in the Treatment of Symptomatic PAD

ESVS Lunch Symposium 57:28